Published in Cancer Weekly, February 22nd, 1999
A. Ritchie and colleagues from the Cancer Trials Office, England, reported early clinical trial results of IFN-(alpha) for the treatment of metastatic renal carcinoma ("Interferon-Alpha and Survival in Metastatic Renal Carcinoma: Early Results of a Randomized Controlled Trial," Lancet, January 2, 1999;353(9146):14-17).
"Metastatic renal carcinoma has a 2-year survival of around 20 percent and is largely resistant to chemotherapy," wrote Ritchie et al. "The use of interferons in the treatment of metastatic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.